Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit ...

March has shocked the rapeseed market, with China announcing 100% tariffs on Canadian rapeseed imports. Volatility is hitting ...

Syncromune ® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform optimized for solid tumor cancers, today announced the appointment of ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

EUR/USD has shed weight for four straight trading days, declining from it’s latest swing high into 1.0950. Fiber is testing ...

As of December 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $151.1 million. The Company believes its current cash and cash equivalents and marketable securities are ...

Signature Aviation has announced that it will be offering its blended sustainable aviation fuel (SAF) at six new locations ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

Bitcoin stalls near $85K as investor focus shifts to Bitcoin Act progress, ETF inflows, and macro risks including tariffs and ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...